Addition of Ruxolitinib to Standard Graft-vs-Host Disease Prophylaxis for Allo-HCT in Patients With Aplastic Anemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Bone Marrow Transplantation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Bone Marrow Transplant 2024 Jul 01;59(7)997-1005, X Zhang, X Zhao, S Chen, M Hao, L Zhang, M Gong, Y Shi, J Wei, P Zhang, S Feng, Y He, E Jiang, M HanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.